SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS)

Q: What does CUSIP 78397T202 represent in this 13F holders report?

CUSIP 78397T202 is the security identifier for SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share in Q3 2025?

34 institutional investors reported SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 78397T202

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 67,297,118
Total 13F shares: 28,023,938
Share change: +26,100,064
Total reported value: $56,328,113
Price per share: $2.01
Number of holders: 34
Value change: +$52,469,483
Number of buys: 22
Number of sells: 6

Quarterly Holders Quick Answers

What is CUSIP 78397T202?
CUSIP 78397T202 identifies SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 78397T202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Vivo Opportunity Fund Holdings, L.P.	13D/G	—	10%	25,931,000	$54,973,720	$0	29 Sep 2025	13D/G
Woodline Partners LP	13D/G	—	9.9%	7,125,881	$14,323,021	$0	30 Sep 2025	13D/G
Commodore Capital LP	13D/G	—	9.9%	4,522,977	$9,588,711	$0	26 Sep 2025	13D/G
Edward D. Hamilton	3/4/5	10%+ Owner	— mixed-class rows	9,456,382 mixed-class rows	$9,348,396	—	22 Oct 2021	3/4/5
Andrew Moin	3/4/5	Director	— mixed-class rows	2,523,807 mixed-class rows	$3,847,299	—	29 Sep 2025	3/4/5
Sessa Capital (Master), L.P.	3/4/5	Director	— mixed-class rows	2,523,807 mixed-class rows	$3,847,299	—	29 Sep 2025	3/4/5
Ilan Katz	3/4/5	Director, 10%+ Owner	— class O/S missing	3,049,325	$2,683,406	—	13 Oct 2021	3/4/5
BVF INC/IL	13F	Company	1.4%	917,826	$1,606,196	—	30 Jun 2025	13F
Sessa Capital IM, L.P.	13F	Company	0.68%	458,457	$804,592	—	30 Jun 2025	13F
VANGUARD GROUP INC	13F	Company	0.42%	282,371	$494,150	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.13%	84,772	$148,371	—	30 Jun 2025	13F
Pathstone Holdings, LLC	13F	Company	0.08%	50,650	$88,891	—	30 Jun 2025	13F
Kovitz Investment Group Partners, LLC	13F	Company	0.03%	19,201	$33,698	—	30 Jun 2025	13F
First PREMIER Bank	13F	Company	0.03%	18,986	$33,000	—	30 Jun 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	17,095	$29,916	—	30 Jun 2025	13F
Kestra Advisory Services, LLC	13F	Company	0.02%	11,930	$20,937	—	30 Jun 2025	13F
Creative Planning	13F	Company	0.02%	11,852	$20,800	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.02%	11,387	$19,984	—	30 Jun 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.02%	11,030	$19,358	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.02%	10,658	$18,705	—	30 Jun 2025	13F
LMR Partners LLP	13F	Company	— class O/S missing	539,588	$17,968	—	30 Jun 2025	13F
BlackRock, Inc.	13F	Company	0.01%	7,006	$12,296	—	30 Jun 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.01%	4,937	$8,639	—	30 Jun 2025	13F
Sachetta, LLC	13F	Company	0.01%	4,100	$7,196	—	30 Jun 2025	13F
MORGAN STANLEY	13F	Company	— mixed-class rows	146,607 mixed-class rows	$5,171	—	30 Jun 2025	13F
Michael G. King Jr.	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	120,000 mixed-class rows	$4,400	—	21 Feb 2024	3/4/5
CLEAR STREET LLC	13F	Company	— class O/S missing	78,833	$2,625	—	30 Jun 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	726	$1,274	—	30 Jun 2025	13F
Walleye Trading LLC	13F	Company	— class O/S missing	31,863	$1,061	—	30 Jun 2025	13F
MAI Capital Management	13F	Company	0%	217	$381	—	30 Jun 2025	13F
GS Investments, Inc.	13F	Company	0%	200	$351	—	30 Jun 2025	13F
WOLVERINE ASSET MANAGEMENT LLC	13F	Company	— class O/S missing	4,620	$153	—	30 Jun 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	87	$152	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	73	$128	—	30 Jun 2025	13F
HARBOUR INVESTMENTS, INC.	13F	Company	0%	50	$88	—	30 Jun 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	50	$88	—	30 Jun 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0%	45	$79	—	30 Jun 2025	13F
NewEdge Advisors, LLC	13F	Company	— class O/S missing	1,072	$35	—	30 Jun 2025	13F
Russell P. Beyer	3/4/5	Chief Financial Officer	— class O/S missing	275,000	—	—	14 Mar 2023	3/4/5
Charles Hiram Randall	3/4/5	Chief Strategy Officer	— mixed-class rows	157,313 mixed-class rows	—	—	22 Oct 2021	3/4/5
Mervyn Turner	3/4/5	Director	— mixed-class rows	79,192 mixed-class rows	—	—	22 Oct 2021	3/4/5
Hua Wu	3/4/5	SVP Research & Product Dev.	— mixed-class rows	43,823 mixed-class rows	—	—	22 Oct 2021	3/4/5
Frederick Finnegan	3/4/5	Chief Business Officer	— class O/S missing	23,453	—	—	16 Mar 2022	3/4/5
Thomas Charles Luke	3/4/5	Chief Medical Officer	— class O/S missing	20,519	—	—	16 Mar 2022	3/4/5
Jeffrey G. Spragens	3/4/5	Director	— class O/S missing	20,000	—	—	15 Jul 2024	3/4/5
Bruce Kipp Erickson	3/4/5	Chief Operating Officer	— class O/S missing	18,196	—	—	16 Mar 2022	3/4/5
Carlos N. Carillo	3/4/5	SVP Regulatory Affairs	— class O/S missing	17,681	—	—	22 Oct 2021	3/4/5
Melissa Vera Ullerich	3/4/5	Chief Communications Officer	— class O/S missing	16,405	—	—	16 Mar 2022	3/4/5
Jerry Lynn Pommer	3/4/5	Chief Compliance Officer	— class O/S missing	15,172	—	—	16 Mar 2022	3/4/5
David Charles Link	3/4/5	Director	— class O/S missing	9,305	—	—	15 Jul 2024	3/4/5

Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) as of Q3 2025

As of 30 Sep 2025, SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) was held by 34 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 28,023,938 shares. The largest 10 holders included Vivo Capital, LLC, RA CAPITAL MANAGEMENT, L.P., Commodore Capital LP, Woodline Partners LP, Sessa Capital IM, L.P., BVF INC/IL, SPHERA FUNDS MANAGEMENT LTD., VANGUARD GROUP INC, HB Wealth Management, LLC, and AWM Investment Company, Inc.. This page lists 34 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.